MedTrace Logo

Molecular Screening for Cancer Treatment Optimization

NCT01566019 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2150

Last updated 2020-02-17

No results posted yet for this study

Summary

The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line.

The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.

Conditions

  • Metastatic Solid Tumors (Any Localization)

Interventions

PROCEDURE

Tumoral biopsy

Every enrolled patient undergoes tumoral biopsy

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Jean-Charles SORIA, MD, PhD · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-28
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01566019 on ClinicalTrials.gov